» Articles » PMID: 33882369

LncRNA CRNDE Promotes the Progression and Angiogenesis of Pancreatic Cancer Via MiR-451a/CDKN2D Axis

Overview
Journal Transl Oncol
Specialty Oncology
Date 2021 Apr 21
PMID 33882369
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The lncRNA colorectal neoplasia differentially expressed (lncRNA CRNDE) has been reported to play a pivotal role in various cancers. However, the expression and function of CRNDE in pancreatic cancer remain unclear. The objective of this study was to investigate the effects of CRNDE on pancreatic cancer and the underlying mechanisms.

Methods: The expression of CRNDE in pancreatic cancer tissues and cell lines was determined by RT-qPCR. Proliferation and angiogenesis were detected by MTT, colony formation, transwell and tube formation assays in vitro and in vivo. ELISA assay was used to detect the secretion of VEGFA. IHC was performed to test the expression levels of Ki67 and CD31. The binding sites between CRNDE, CDKN2D and miR-451a were predicted by bioinformatics analysis. Dual luciferase reporter and RNA immunoprecipitation assays were conducted to confirm the interaction with each other.

Results: The results showed that CRNDE was significantly up-regulated in pancreatic cancer tissues as well as cell lines. CRNDE overexpression promoted the progression and angiogenesis of pancreatic cancer cells in vitro and in vivo. Moreover, we identified that CRNDE functioned as a sponge for miR-451a and CRNDE overexpression inhibited the expression of miR-451a. Furthermore, we confirmed that miR-451a directly interacted with CDKN2D and negatively regulated CDKN2D expression. In addition, CRNDE was found to positively regulate CDKN2D expression and mediate pancreatic cancer cell proliferation and angiogenesis through miR-451a/CDKN2D axis.

Conclusion: CRNDE modulates cell proliferation and angiogenesis via miR-451a/CDKN2D axis in pancreatic cancer, which provides a potential therapeutic target for pancreatic cancer treatment.

Citing Articles

TFAP2A-regulated CRNDE enhances colon cancer progression and chemoresistance via RIPK3 interaction.

Gao X, Huang Y, Wei T, Xue J, Iurii F, Yang L Funct Integr Genomics. 2025; 25(1):36.

PMID: 39954131 PMC: 11829933. DOI: 10.1007/s10142-025-01545-w.


Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy.

Yu G, Nanding A Mol Cell Biochem. 2024; .

PMID: 39636431 DOI: 10.1007/s11010-024-05168-w.


Human erythrocytes' perplexing behaviour: erythrocytic microRNAs.

Joshi U, Jani D, George L, Highland H Mol Cell Biochem. 2024; 480(2):923-935.

PMID: 39037663 DOI: 10.1007/s11010-024-05075-0.


Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis.

Razavinia A, Razavinia A, Jamshidi Khalife Lou R, Ghavami M, Shahri F, Tafazoli A Heliyon. 2024; 10(12):e32875.

PMID: 38948044 PMC: 11211897. DOI: 10.1016/j.heliyon.2024.e32875.


LncRNA CRNDE promotes hepatoma cell proliferation by regulating the metabolic reprogramming of M2 macrophages via ERK pathway.

Lin C, Jiang T, E C, Wang L, Chen T, Wang X Cancer Cell Int. 2024; 24(1):193.

PMID: 38822362 PMC: 11143606. DOI: 10.1186/s12935-024-03380-8.